Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $7.50

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.50.

Several equities analysts recently commented on GANX shares. BTIG Research restated a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. Oppenheimer restated an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, August 31st.

Gain Therapeutics Stock Performance

GANX opened at $1.75 on Wednesday. The business has a fifty day simple moving average of $1.83 and a 200 day simple moving average of $1.94. The company has a market capitalization of $76.37 million, a PE ratio of -3.50 and a beta of 0.20. Gain Therapeutics has a 1 year low of $1.53 and a 1 year high of $4.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. Research analysts expect that Gain Therapeutics will post -0.5 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP acquired a new position in Gain Therapeutics in the 2nd quarter valued at $1,283,000. Potomac Capital Management Inc. bought a new stake in shares of Gain Therapeutics during the 4th quarter valued at $3,252,000. Virtu Financial LLC grew its holdings in shares of Gain Therapeutics by 126.9% during the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after purchasing an additional 30,207 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics during the 3rd quarter worth $68,000. Finally, Wealthspire Advisors LLC bought a new position in shares of Gain Therapeutics in the fourth quarter worth $54,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.